KGF ameliorates GVHD in a nonconditioned SCID model.
Different KGF schedules and T-cell transfer doses are shown. In panels A (survival) and B (weights), BALB/c SCID mice received PBS (■) or KGF on days −3, −2, and −1 pretransfer (▪) of 2 × 106 C57BL/6 LN T cells or days 0 to 6 after transfer (●) as shown (P < .007 for survival of KGF mice vs PBS, n = 5 per group). In panels C (survival) and D (weights), BALB/c SCID mice received PBS or KGF on days 0, 1, 2, and 3 after transfer of either 0.5 (○, PBS; ●, KGF) or 2 × 106 (■, PBS; ▪, KGF) C57BL/6 LN T cells as shown (P < .001 for survival of KGF vs non-KGF counterparts, n = 5 per group). In panels E (survival) and F (weights), BALB/c SCID mice received PBS (■) or KGF (▪) on days 0 to 6 after transfer of 106 C57BL/6 LN T cells (P < .001 for survival of KGF vs PBS, n = 10 per group).
